- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Myelofibrosis: Characteristics and Subtypes
Aaron Gerds, MD, MS, reviews myeloid disorder myelofibrosis and presents diverse symptoms, from blood count variations to spleen enlargement.
EP: 1.Myelofibrosis: Characteristics and Subtypes
EP: 2.NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
EP: 3.Understanding Myelofibrosis: Disease Spectrum and Impact on Quality of Life
EP: 4.Prognosis and Treatment Strategies in Myelofibrosis: Risk Assessment and Therapeutic Goals
EP: 5.NCCN Guidelines 2023: Updates in Myelofibrosis Management
EP: 6.NCCN Guidelines: Categories and Recommendations in Myelofibrosis
EP: 7.Integrating Momelotinib: NCCN Guidelines and Drug Comparison
EP: 8.Monitoring Myelofibrosis Treatment Response: Guidelines and Considerations
EP: 9.Future of Myelofibrosis: Anticipated Data and Emerging Therapies
This is a video synopsis/summary of a Guidelines featuring Aaron Gerds, MD, MS.
Myelofibrosis, a myeloproliferative neoplasm, manifests in variable blood counts and constitutional symptoms. Gerds explains its impact, causing cytokine-driven symptoms like night sweats and spleen enlargement. The disease's clonal nature poses a risk of progression to the blast phase, a highly aggressive stage. Understanding these clinical aspects is crucial for effective management.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
NCCN Guidelines Prioritize Quad Therapy in Multiple Myeloma
November 26th 2024In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.
Read More
DMD Guidance Could Benefit From Update, Experts Say
January 24th 2024MEDLINE, the Turning Research Into Practice database, Google Scholar, and organization guidelines were searched for their ongoing applicability to the management of Duchenne muscular dystrophy (DMD) and to determine if there is a need to develop new treatment recommendations.
Read More
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
NCCN Guidelines Update Recommends Ropeginterferon Alfa-2b for Polycythemia Vera
July 7th 2023Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
Read More
NCCN Adds Epcoritamab to Clinical Practice Guidelines in Oncology for DLBCL
June 23rd 2023Epcoritamab has been added to the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for B-cell Lymphomas in the third- or later-line setting for the treatment of patients with diffuse large B-cell lymphoma.
Read More
Review Finds EORTC QLQ-MY20 Useful, Robust 25 Years After Development
June 16th 2023The treatment landscape for multiple myeloma has shifted since European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20) was first developed in 1996.
Read More
